Jan 23, 2019 - Top Research Reports for Amazon, Verizon & AbbVie
Jan 23, 2019 - AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.
Jan 22, 2019 - EDP-305 is presumed to be a new generation Farnesoid X receptor agonist and its lead investigative drug candidate.EDP-305 is a metabolism modulator currently in Phase 2 clinical trials for NASH and Pr
Jan 22, 2019 - A high degree of financial leverage means high interest payments, which affect the company's bottom line. So, investors try to avoid stocks that bear large debt loads
Jan 21, 2019 - AbbVie's (ABBV) Imbruvica falls short of meeting the primary endpoint of PFS or OS benefit in a phase III study that probed its combo usage in first-line metastatic pancreatic cancer.
Jan 21, 2019 - The S&P 500 has had an impressive 13.7% rally since its December 24th lows.Many of the most violently beaten down stocks of the correction are now soaring hard and fast, leaving many investors wonderi
Jan 21, 2019 - Zacks Value Trader Highlights: Crocs, Five Below, AbbVie and J.Jill
Jan 21, 2019 - Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.
Jan 18, 2019 -
Jan 18, 2019 - AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.